Key result
Arrhythmogenic right ventricular cardiomyopathy/dysplasia causes up to 20% of sudden cardiac deaths in young people <35 years of age and is managed with pharmacotherapy, ICDs, or transplantation.
Answers are grounded in this paper and cite their sources.
This review summarizes the clinical presentation, diagnosis, and management of arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D).
Arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D) is an inherited myocardial disease characterized by fibro-fatty replacement of the right ventricular myocardium, and associated with paroxysmal ventricular arrhythmias and sudden cardiac death (SCD). It is currently the second most common cause of SCD after hypertrophic cardiomyopathy in young people <35 years of age, causing up to 20% of deaths in this patient population. This condition has a male preponderance and is more commonly found in individuals of Italian and Greek descent. To date, there is no single diagnostic test for ARVC/D and the diagnosis is made based on clinical, electrocardiographic, and radiological findings according to the Revised 2010 Task Force Criteria. In this review, we will discuss the mainstay treatment which includes pharmacotherapy, implantable cardioverter-defibrillator insertion for abortion of sudden cardiac death, and in the advanced stages of the disease cardiac transplantation.
No takes yet. Share an insight, caveat, or question.
Li et al. (2017) conducted a review in Arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D). Arrhythmogenic right ventricular cardiomyopathy/dysplasia causes up to 20% of sudden cardiac deaths in young people <35 years of age and is managed with pharmacotherapy, ICDs, or transplantation.
Synapse has enriched 10 related papers. Consider them for comparative context: